4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide
| Title | Journal |
|---|---|
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. | Lancet (London, England) 20180324 |
| Neuroendocrine cancer: SELECT—lenvatinib in thyroid cancer. | Nature reviews. Clinical oncology 20150401 |
| Lenvatinib: first global approval. | Drugs 20150401 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. | Journal of medicinal chemistry 20121227 |
| A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. | British journal of cancer 20120508 |
| Novel molecular targeted therapies for refractory thyroid cancer. | Head & neck 20120501 |
| Unique metabolic pathway of [(14)C]lenvatinib after oral administration to male cynomolgus monkey. | Drug metabolism and disposition: the biological fate of chemicals 20120401 |
| Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120301 |
| Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. | International journal of cancer 20110801 |
| E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. | Molecular cancer therapeutics 20110701 |
| Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110415 |
| Antiangiogenic therapies for malignant pleural mesothelioma. | Frontiers in bioscience (Landmark edition) 20110101 |
| E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. | BMC cancer 20110101 |
| Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. | European journal of medicinal chemistry 20101101 |
| A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. | Journal of pharmacokinetics and pharmacodynamics 20100801 |
| E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091201 |
| Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080901 |
| E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. | International journal of cancer 20080201 |